The use of anti-obesity therapy as indicated in IBD patients remains limited; although, reassuringly, GLP-1 based therapies appear to be safe and beneficial in obese patients with IBD and this should be encouraged in clinical practice. This evidence concerns the gene GCG and Obesity.